{
    "nctId": "NCT06411678",
    "briefTitle": "Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer",
    "officialTitle": "Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "The evaluation of diagnostic performance of 68Ga-DOTA-dPNE PET in breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1: Age: \u226518 years old female, expected survival \u226512 weeks; 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis; 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion; 4: Obtain written informed consent and be able to follow up\n\nExclusion Criteria:\n\n* 1: Severe liver and kidney dysfunction; 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study; 3: Individuals unable to lie flat for thirty minutes; 4: Suffers from claustrophobia or other mental illnesses; 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study; 6: Refuses to join this clinical study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}